CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer's disease

Published: 22-07-2020| Version 1 | DOI: 10.17632/v6gjkzggfr.1
Gamze Ates


This dataset contains the raw data obtained for the DARTS/proteomics and the metabolomics analyses performed to identify the putative target of CMS121, an Alzheimer's disease drug candidate. We refer to the published manuscript for more detailed information: